<DOC>
	<DOCNO>NCT02375620</DOCNO>
	<brief_summary>The study evaluate optimal dose treatment SGA short stature child Pegylated Somatropin , initially evaluate efficiency safety treatment SGA short stature child provide scientific , reliable basis phase III clinical trial dose selection .</brief_summary>
	<brief_title>Clinical Study Pegylated Somatropin ( PEG Somatropin ) Treat SGA Children With Short Stature</brief_title>
	<detailed_description>This multicenter , randomize phase II study , half participant receive high dose , half receive low dose .</detailed_description>
	<criteria>The patient diagnose clinically full term small gestational age infant . Girl 36 year old , boys 37 year old . Be preadolescence ( Tanner stage 1 ) . The child achieve catchup growth he/she enter group ( definition catchup growth height high third percentile age gender ) ( Appendix 2 3 ) . The height child shorter 2SDS median normal child age gender he/she enter group ( mean height height standard deviation normal child age gender normal child regard height data physical development investigation data child age 018 9 city China ( 2005 ) standard [ 13 ] , Appendix 4 5 ) . Within year enter group , growth hormone stimulation test , peak concentration growth hormone serum &gt; 10 µg/L . Bone age≤ actual age+1 . The function glucose regulation normal : fasting blood glucose &lt; 5.6mmol/L . Birth gestational age ≥ 37 week . The subject guardians sign inform consent ( subject lack ability signing informed consent , legal guardian write subject name instead ) . People abnormal liver kidney function ( ALT &gt; 2 time upper limit normal value , Cr &gt; upper limit normal value ) . Patients positive hepatitis B core antigen ( HBc ) , hepatitis B surface antigen ( HBsAg ) hepatitis B e antigen ( HBeAg ) . People know highly allergic constitution allergy drug excipient study . People diabetes , severe cardiopulmonary , hematological system malignant tumor diseases general infection , immune deficiency patient mental disease . Other abnormal growth development , Turner syndrome , Laron syndrome , growth hormone receptor deficiency . Potential tumor patient ( family history ) . Patients used growth hormone treatment . Subjects take part clinical trial study within 3 month . Patients use hormonal treatment within 3 month ( sex hormone , glucocorticoid etc. , treat month ) receive drug treatment may interfere secretion GH GH function ( oxandrolone , growth hormone release hormone etc . ) ; Other condition opinion investigator preclude enrollment study .</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>7 Years</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>